nach oben

Erschienen in:

18.09.2017 | Stammzell-Transplantation | fortbildung

Ergänzung oder Alternative zur Chemotherapie?

RETRACTED ARTICLE: Immuntherapie des multiplen Myeloms

verfasst von: Katja Weisel, Prof. Dr. med. Lothar Kanz

Erschienen in: InFo Hämatologie + Onkologie | Sonderheft 1/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Zulassung von zwei monoklonalen Antikörpern für die Behandlung des multiplen Myeloms (MM) im Jahr 2016 durch die europäische Arzneimittel-Agentur (EMA) hat eine neue Ära in der zielgerichteten Immuntherapie des MM eingeleitet. Mittlerweile stehen verschiedene neue Ansätze in der Immuntherapie des MM zur Verfügung, die auf unterschiedlichen Therapiestrategien basieren.

Morgan GJ et al. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12(5):335–48.CrossRef

Walker BA et al. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. J Clin Oncol. 2015;33(33):3911–20.CrossRef

Kristinsson SY et al. Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica. 2012;97(6):854–8.CrossRef

Romano A et al. Immunological dysregulation in multiple myeloma microenvironment. Biomed Res Int. 2014;2014:198539.PubMedPubMedCentral

Liu J et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-ã and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 2007;110(1):296–304.CrossRef

Prabhala RH et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010;115(26):5385–92.CrossRef

Bryant C et al. Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood Cancer J. 2013;3:e148.CrossRef

Khoo TL et al. Interferon-alpha in the treatment of multiple myeloma. Curr Drug Targets. 2011;12(3):437–46.CrossRef

San-Miguel J et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood. 2014;123(26):4136–42.CrossRef

10.

Hansson M et al. A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2015;21(12):2730–6.CrossRef

11.

Spencer AP et al. A phase I study of the anti-kappa monoclonal antibody, MDX-1097, in previously treated multiple myeloma patients. J Clin Oncol. 2010;28(15_suppl):Abstr 8143.CrossRef

12.

Hsi ED et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14(9):2775–84.CrossRef

13.

Balasa B et al. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways. Cancer Immunol Immunother. 2015;64(1):61–73.CrossRef

14.

Lonial S et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012;30(16):1953–9.CrossRef

15.

Lonial S et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015;373(7):621–31.CrossRef

16.

Jakubowiak AJ et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol. 2012;30(16):1960–5.CrossRef

17.

Lokhorst HM et al. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015;373(13):1207–19.CrossRef

18.

Lonial S et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551–60.CrossRef

19.

de Weers M et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840–8.CrossRef

20.

Krejcik J et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384–94.CrossRef

21.

Casneuf T et al. Pharmacodynamic Relationship between Natural Killer Cells and Daratumumab Exposure in Relapsed/Refractory Multiple Myeloma. Haematologica 2016;101(S 1):87–8.

22.

Dimopoulos MA et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;375(14):1319–31.CrossRef

23.

Palumbo A et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;375(8):754–66.CrossRef

24.

Weisel K et al. Efficacy of Daratumumab in Combination with Lenalidomide Plus Dexamethasone (DRd) or Bortezomib Plus Dexamethasone (DVd) in Relapsed or Refractory Multiple Myeloma RRMM) Based on Cytogenetic Risk Status. J Clin Oncol. 2017;35(15_suppl):8006.CrossRef

25.

Perez-Andres M et al. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia. 2005;19(3):449–55.CrossRef

26.

de Haart SJ et al. Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance. Haematologica. 2016;101(8):e339–42.CrossRef

27.

Tembhare P et al. Antigenic drift in relapsed extramedullary multiple myeloma: plasma cells without CD38 expression. Leuk Lymphoma. 2012;53(4):721–4.CrossRef

28.

Martin TS et al. A Phase I Trial of Sar650984, a Cd38 Monoclonal Antibody, in Relapsed or Refractory Multiple Myeloma. Haematologica. 2014;99:519–519.CrossRef

29.

Raab MS et al. A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma. Blood. 2016;128(22):1152.

30.

Rotolo A et al. The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma. Br J Haematol. 2016;173(3):350–64.CrossRef

31.

Linette GP et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122(6):863–71.CrossRef

32.

Maude SL et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17.CrossRef

33.

Garfall AL et al. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N Engl J Med. 2015;373(11):1040–7.CrossRef

34.

Garfall AL et al. Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR)-modified autologous T cells (CTL019) in advanced multiple myeloma. J Clin Oncol. 2015;33(15, Suppl):Abstr 8517.

35.

Maude SL et al. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017–23.CrossRef

36.

Xu XJ, Tang YM. Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. Cancer Letters. 2014;343(2):172–8.CrossRef

37.

Ali SA et al. Remissions of Multiple Myeloma during a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor. Blood. 2015;126(23):LBA-1.

38.

Duell J et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia. 2017 Feb 24. [Epub ahead of print].

39.

Lesokhin AM et al. Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies. Blood. 2014;124(21):291.

40.

San Miguel J et al. Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023. Blood. 2015;126(23):505.

41.

Garban F et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006;107(9):3474–80.CrossRef

42.

Rosinol L et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood. 2008;112(9):3591–3.CrossRef

43.

Bjorkstrand B et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol. 2011;29(22):3016–22.CrossRef

44.

Knop S et al. Autologous Followed By Allogeneic Versus Tandem-Autologous Stem Cell Transplant in Newly Diagnosed FISH-del13q Myeloma. Blood. 2014;124(21):43.

45.

Bruno B et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356(11):1110–20.CrossRef

46.

Krishnan A et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011;12(13):1195–203.CrossRef

47.

Lokhorst HM et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood. 2012;119(26):6219–25.CrossRef

Titel: Ergänzung oder Alternative zur Chemotherapie?
RETRACTED ARTICLE: Immuntherapie des multiplen Myeloms
verfasst von: Katja Weisel
Prof. Dr. med. Lothar Kanz
Publikationsdatum: 18.09.2017
Verlag: Springer Medizin
Schlagwörter: Stammzell-Transplantation
Multiples Myelom
Stammzell-Transplantation
CAR-T-Zellen
Stammzell-Transplantation
Daratumumab
Elotuzumab
Erschienen in: InFo Hämatologie + Onkologie / Ausgabe Sonderheft 1/2017
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI: https://doi.org/10.1007/s15004-017-5793-6

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

RETRACTED ARTICLE: Immuntherapie des multiplen Myeloms

Zusammenfassung

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2017

TBP-Konzept auch in der Immunonkologie

Immuntherapie beim Hodgkin-Lymphom

Aktuelle Immuntherapien des malignen Melanoms

SLAMF7-Antikörper beim multiplen Myelom

Immuntherapie von akuten Leukämien: immer mehr Optionen

CME: Management immunvermittelter Nebenwirkungen

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie